Individualised Estimation of Quality-adjusted Survival Benefit and Cost-effectiveness of Proton Beam Therapy in Intermediate-stage Hodgkin Lymphoma.
Journal article
Jones DA. et al, (2023), Clin Oncol (R Coll Radiol)
P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
Journal article
Jones D. et al, (2022), HemaSphere, 6, 43 - 44
Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry.
Journal article
Jones DA. et al, (2022), Blood Adv, 6, 909 - 919